| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00000658-200110000-00009 |
| P8608 | Fatcat ID | release_3duvcrnp2bdlrij4edwjferuly |
| P932 | PMC publication ID | 1422073 |
| P698 | PubMed publication ID | 11573043 |
| P5875 | ResearchGate publication ID | 11775356 |
| P50 | author | Jeffrey A Norton | Q92191219 |
| Douglas L. Fraker | Q123195653 | ||
| H. Richard Alexander | Q123195986 | ||
| P2093 | author name string | R T Jensen | |
| D J Venzon | |||
| F Gibril | |||
| P2860 | cites work | Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. | Q33766915 |
| Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. | Q33921582 | ||
| Are patients with multiple endocrine neoplasia type I prone to premature death? | Q34064454 | ||
| Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients | Q34729926 | ||
| Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome | Q35272709 | ||
| Prognostic factors in patients with endocrine tumours of the duodenopancreatic area | Q35352149 | ||
| The MEA-I syndrome: an all or none phenomenon? | Q39266266 | ||
| Apparent lymph node primary gastrinoma | Q40646390 | ||
| Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. | Q40841123 | ||
| Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome | Q40845787 | ||
| Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. | Q41012844 | ||
| Multiple endocrine neoplasia type I. Surgical therapy | Q41515514 | ||
| Surgery to cure the Zollinger-Ellison syndrome | Q41686955 | ||
| Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. | Q42458826 | ||
| Location, incidence, and malignant potential of duodenal gastrinomas | Q42468443 | ||
| Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. | Q42497648 | ||
| Microgastrinomas of the duodenum. A cause of failed operations for the Zollinger-Ellison syndrome | Q43724851 | ||
| Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study | Q44637821 | ||
| Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma | Q44748811 | ||
| Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia | Q44878332 | ||
| Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. | Q45163109 | ||
| The Zollinger-Ellison syndrome. A collective surgical experience | Q46042442 | ||
| Surgical treatment of localized gastrinoma within the liver: a prospective study. | Q46963385 | ||
| Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy | Q47424929 | ||
| Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. | Q50639178 | ||
| Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. | Q51599587 | ||
| Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. | Q51618363 | ||
| Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. | Q52887975 | ||
| Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. | Q54527768 | ||
| Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment | Q67522369 | ||
| Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study | Q68052387 | ||
| Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study | Q68582798 | ||
| Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study | Q71112902 | ||
| Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1 | Q71568271 | ||
| The role of surgery in the Zollinger-Ellison syndrome | Q71724899 | ||
| Clinical studies of multiple endocrine neoplasia type 1 (MEN1) | Q71777163 | ||
| Distinguishing small hepatic hemangiomas from vascular liver metastases in gastrinoma: use of a somatostatin-receptor scintigraphic agent | Q71955966 | ||
| Cause of death in multiple endocrine neoplasia type 1 | Q72220849 | ||
| Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study | Q72281843 | ||
| MEN I pancreas: A histological and immunohistochemical study | Q72746929 | ||
| A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas | Q72860964 | ||
| Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management | Q73047885 | ||
| Surgical strategy for large or malignant endocrine pancreatic tumors | Q73093382 | ||
| A personal experience with pancreatic and duodenal neuroendocrine tumors | Q73152293 | ||
| Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? | Q73292276 | ||
| Zollinger-Ellison syndrome. Clinical presentation in 261 patients | Q73360415 | ||
| Malignant endocrine tumors in patients with MEN 1 disease | Q73375839 | ||
| A prospective analysis of the frequency, location, and curability of ectopic (nonpancreaticoduodenal, nonnodal) gastrinoma | Q74029000 | ||
| Lethality of multiple endocrine neoplasia type I | Q74580275 | ||
| Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1 | Q74817189 | ||
| Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both | Q74817194 | ||
| Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size | Q77687431 | ||
| Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE) | Q77917882 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple endocrine neoplasia | Q1553018 |
| multiple endocrine neoplasia type 1 | Q3347154 | ||
| patient | Q181600 | ||
| P304 | page(s) | 495-505; discussion 505-6 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | Annals of Surgery | Q4767866 |
| P1476 | title | Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome | |
| P478 | volume | 234 |
| Q36661917 | A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors |
| Q36085109 | Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome |
| Q30319804 | Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers |
| Q37808142 | Care for patients with multiple endocrine neoplasia type 1: the current evidence base |
| Q37056120 | Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors |
| Q49957735 | Current and emerging therapies for PNETs in patients with or without MEN1. |
| Q38378959 | Determinants of surgical resection for pancreatic neuroendocrine tumors. |
| Q37016985 | Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1). |
| Q82626635 | Diagnosis and treatment of Zollinger Ellison syndrome in a morbidly obese patient after Roux-en-Y gastric bypass |
| Q50075239 | Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing |
| Q51530644 | Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? |
| Q34248466 | ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors |
| Q24603675 | ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes |
| Q37785239 | Endocrine Cancer Predisposition Syndromes: Hereditary Paraganglioma, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, and Hereditary Thyroid Cancer |
| Q31030383 | Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas |
| Q28290833 | Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors |
| Q37146881 | Inherited endocrinopathies: an update |
| Q24647838 | Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies |
| Q90172874 | Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors |
| Q97880480 | Islet Tumors: Resect or Follow? |
| Q36179244 | Lessons from genes mutated in multiple endocrine neoplasia (MEN) syndromes. |
| Q84629509 | Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1 |
| Q45837233 | Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. |
| Q83300174 | Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 |
| Q34345074 | Mechanism of acid hypersecretion post curative gastrinoma resection |
| Q36063577 | Multiple Endocrine Neoplasia: Genetics and Clinical Management |
| Q79172144 | Multiple endocrine neoplasia type 1 |
| Q36739108 | Multiple endocrine neoplasia type 1- presenting multiple lipomas and hypoglycemia onset |
| Q35001777 | NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas |
| Q81573105 | Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1 |
| Q79775342 | Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias |
| Q35065094 | Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection |
| Q87426224 | Pancreatic neuroendocrine tumors |
| Q36632665 | Pharmacotherapy of Zollinger-Ellison syndrome |
| Q46831174 | Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study |
| Q46191004 | Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome |
| Q92549052 | Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG) |
| Q37279937 | Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. |
| Q73692399 | Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas |
| Q37797353 | Reoperative Surgery for the Zollinger-Ellison Syndrome |
| Q35922060 | Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome |
| Q45196036 | Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value |
| Q80154242 | Surgery increases survival in patients with gastrinoma |
| Q34584654 | Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1. |
| Q90136088 | Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies |
| Q37511722 | Surgical management of pancreatic endocrine tumors |
| Q42352980 | Surgical treatment of multiple spine metastases from gastrinoma |
| Q36113256 | The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. |
| Q54638848 | Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. |
| Q34453043 | Update on pancreatic neuroendocrine tumors |
| Q51537968 | Zollinger-Ellison Syndrome. |
| Q34390574 | Zollinger-Ellison syndrome: classical considerations and current controversies. |
| Q38150165 | Zollinger-Ellison syndrome: recent advances and controversies |
| Q81529058 | [Prophylactic pancreas surgery] |
| Q83868851 | [The gastric antrum: a rare primitive location of a gastrinoma within a type I multiple endocrine neoplasia] |
Search more.